EyePoint Inc. (EYPT)
EYPT trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/0001193125-26-093917-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EYPT on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001314102 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $31.4M |
| Net income | -$232.0M |
| Operating income | -$243.4M |
| Net margin | -739.4% |
| Operating margin | -776.0% |
| Revenue growth | -27.5% |
| Cash | $101.8M |
| Total assets | $364.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions and events raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $83.2M cash; operating cash flow -$73.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 113,782,597 (2026-11-06); 82,787,220 a year earlier; 35,309,432 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $72K, sold $2.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | $756K | -$95.6M | -$86.8M | $83.2M | No debt tags | $2.6M | 10-Q 2026-11-12 |
| Q4 2026 2026-06-30 | $507K | -$94.5M | -$62.3M | $110.5M | No debt tags | $2.8M | 10-Q 2026-08-05 |
| Q3 2026 2026-03-31 | $696K | -$84.8M | -$80.5M | $77.7M | No debt tags | $7.6M | 10-Q 2026-05-07 |
| Q2 2026 2025-12-31 | $620K | -$67.6M | -$65.0M | $101.8M | No debt tags | $31.4M | 10-K 2026-03-05 |
| Q1 2026 2025-09-30 | $966K | -$59.7M | -$59.4M | $74.6M | No debt tags | $42.3M | 10-Q 2026-11-12 |
| Q4 2025 2025-06-30 | $5.3M | -$59.4M | -$62.6M | $71.1M | No debt tags | $51.9M | 10-Q 2026-08-05 |
| Q3 2025 2025-03-31 | $24.5M | -$45.2M | -$53.1M | $85.2M | No debt tags | $56.0M | 10-Q 2026-05-07 |
| Q2 2025 2024-12-31 | $11.6M | -$41.4M | -$35.8M | $99.7M | No debt tags | $43.3M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-06 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.9% |
| 1 month | -89.9% |
| 3 months | -97.7% |
| Year to date | -98.3% |
| 1 year | -97.3% |
| From 52-week high | -98.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| CIRC | Circle8 Group Inc. | $0.1702 | -7.30% | $20.0M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| BNGO | Bionano Genomics Inc. | $0.9400 | -6.00% | $13.1M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| ASTC | Astrotech Corporation (DE) | $3.76 | -10.48% | $8.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier